Delving into the Latest Updates on Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) with Synapse

Overview

Basic Info

Drug Type

Autologous CAR-T

Synonyms

anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine)

Target

CD19 x CD22

Mechanism

CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD22 inhibitors(CD22 inhibitors), Immunologic cytotoxicity

+ [1]

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication

Philadelphia positive acute lymphocytic leukaemiaCD19-positive B-cell acute lymphoblastic leukemiaResidual Neoplasm

Inactive Indication-

Originator Organization

Shanghai First People's Hospital

Active Organization

Shanghai First People's Hospital

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

To evaluate the safety and efficacy of Dasatinib plus CD19/CD22 Bispecific CAR-T for the treatment of elderly Ph-positive lymphoblastic leukemia. Newly diagnosed Ph-positive patients will be given Dasatinib plus VP chemotherapy for induction treatment,if a hematologic complete remission was observed then a lymphocyte collection will be administrated to patients. Then chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19/CD22 CAR+ T cells

Start Date01 Mar 2021

Sponsor / Collaborator

Shanghai First People's Hospital

NCT03919526 / CompletedPhase 1IIT

The Safety and Clinical Efficacy of Human CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR)-T Cell Therapy for Subjects With Measurable Residual Disease(MRD)-Positive B Cell Acute Lymphoblastic Leukemia

To evaluate the safety and efficacy of CD19/CD22 Bispecific chimeric antigen receptor (CAR)-T for the treatment of measurable residual disaese (MRD)-positive B cell acute lymphoblastic leukemia. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19/CD22 CAR+ T cells.

Start Date11 Aug 2019

Sponsor / Collaborator

Shanghai First People's Hospital

100 Clinical Results associated with Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine)

Login to view more data

100 Translational Medicine associated with Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine)

Login to view more data

100 Patents (Medical) associated with Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine)

Login to view more data

20

Literatures (Medical) associated with Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine)

01 Jun 2024·JAMA Oncology

Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia

Article

Author: Ruff, Christer Alexander ; Hensen, Luca ; Faul, Christoph ; Schneider, Dina ; Lengerke, Claudia ; Bethge, Wolfgang Andreas ; Phely, Laurent

This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells.

14 Nov 2023·Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia].

Article

Author: Guan, H H ; Zhao, D F ; Hou, R F ; Yan, H ; Lin, Y H ; An, L L ; Tong, C R ; Wu, T ; Liu, S Y

Objective: To observe the treatment response of a two-dose regimen of inotuzumab ozogamicin (inotuzumab), a monoclonal antibody targeting CD22, for patients with heavily treated relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), including those failed or relapsed after chimeric antigen receptor (CAR) -T-cell therapy. Methods: Pediatric and adult patients who received two doses of inotuzumab and who were evaluated after inotuzumab treatment were included. Antibody infusions were performed between March 2020 and September 2022. All patients expressed CD22 antigen as detected by flow cytometry (>80% leukemic cells displaying CD22) before treatment. For adults, the maximum dosage per administration was 1 mg (with a total of two administrations). For children, the maximum dosage per administration was 0.85 mg/m(2) (no more than 1 mg/dose; total of two administrations). The total dosage administered to each patient was less than the standard dosage of 1.8 mg/m(2). Results: Twenty-one patients with R/R B-ALL were included, including five children (<18 years old) and sixteen adults. Seventeen patients presented with 5.0% -99.0% leukemic blasts in the bone marrow/peripheral blood or with extramedullary disease, and four patients were minimal residual disease (MRD) -positive. Fourteen patients underwent both CD19 and CD22 CAR-T-cell therapy, four underwent CD19 CAR-T-cell therapy, and three underwent blinatumomab therapy. Eleven patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). After inotuzumab treatment, 14 of 21 patients (66.7% ) achieved a complete response (CR, one was MRD-positive CR), and all four MRD-positive patients turned MRD-negative. Four of six patients who failed recent CD22 CAR-T-cell therapy achieved a CR after subsequent inotuzumab treatment. Seven patients (33.3% ) demonstrated no response. Grade 1-3 hepatotoxicity occurred in five patients (23.8% ), one child with no response experienced hepatic veno-occlusive disease (HVOD) during salvage transplantation and recovered completely. Conclusion: For patients with heavily treated R/R B-ALL, including those who had undergone allo-HSCT and CD19/CD22 CAR-T-cell therapy, the two-dose regimen of inotuzumab resulted in a CR rate of 66.7%, and the frequency of hepatotoxicity and HVOD was low.

01 Oct 2023·Cancer research and treatment

Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient.

Author: Zou, Rui ; Jin, Zhengming ; Xia, Fan ; Kang, Liqing ; Wang, Peng ; Yu, Lei ; Liu, Hailing ; Wu, Depei ; Zhou, Xiao ; Qu, Changju

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive non-Hodgkin's lymphoma that affects the brain, eyes, cerebrospinal fluid, or spinal cord without systemic involvement. The outcome of patients with PCNSL is worse compared to patients with systemic diffuse large B-cell lymphoma. Given potential mortality associated with severe immune effector cell-associated neurotoxicity syndrome (ICANS), patients with PCNSL have been excluded from most clinical trials involving chimeric antigen receptor T-cell (CAR-T) therapy initially. Here, we report for the first time to apply decitabine-primed tandem CD19/CD22 dual-targeted CAR-T therapy with programmed cell death-1 (PD-1) and Bruton's tyrosine kinase (BTK) inhibitors maintenance in one patient with multiline-resistant refractory PCNSL and the patient has maintained complete remission (CR) for a 35-month follow-up period. This case represents the first successful treatment of multiline resistant refractory PCNSL with long-term CR and without inducing ICANS under tandem CD19/CD22 bispecific CAR-T therapy followed by maintenance therapy with PD-1 and BTK inhibitors. This study shows tremendous potential in the treatment of PCNSL and offers a look toward ongoing clinical studies.

100 Deals associated with Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Philadelphia positive acute lymphocytic leukaemia	Phase 1	CN	Shanghai First People's Hospital	01 Mar 2021
CD19-positive B-cell acute lymphoblastic leukemia	Phase 1	CN	Shanghai First People's Hospital	11 Aug 2019
Residual Neoplasm	Phase 1	CN	Shanghai First People's Hospital	11 Aug 2019